2025
SJR Q1
JCR Q1 · 5,5
OA
216 matched articles
SCIE
Journal detail
Antibiotics
- Publisher
- Multidisciplinary Digital Publishing Institute (MDPI)
- Country
- Switzerland · Western Europe
- Type
- journal
- ISSN
-
20796382
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,276
- Quartile Q1
- H-Index 124
- Cites/doc 5,83
- Docs (3y) 4.787
- Cites (3y) 29.079
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 5,5
- 5Y JIF 5,7
- JCI 1,16
WoS indexes
- SCIE
Subject classification
Categories (SJR)
Areas
WoS categories
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,276 | 5,5 | 5,7 | 1,16 | Q1 | 124 |
| 2024 | Q1 | Q1 | 1,114 | 4,6 | 4,9 | 1,15 | Q1 | 99 |
| 2023 | Q1 | Q1 | 0,92 | 4,3 | 4,6 | 1,06 | Q1 | 99 |
| 2022 | Q1 | Q1 | 0,792 | 4,8 | 4,9 | 0,98 | Q1 | 99 |
| 2021 | Q1 | Q1 | 0,785 | 5,2 | 5,4 | 0,9 | Q2 | 99 |
| 2020 | Q1 | Q2 | 0,96 | 4,6 | 4,8 | 1 | Q2 | 99 |
| 2019 | Q1 | Q1 | 1,173 | 3,9 | — | 0,94 | Q2 | 99 |
| 2018 | — | Q2 | — | 2,9 | — | 0,69 | Q3 | — |
| 2017 | Q1 | — | 1,063 | — | — | — | — | 99 |
| 2016 | Q1 | — | 0,714 | — | — | — | — | 99 |
| 2015 | Q2 | — | 0,44 | — | — | — | — | 99 |
| 2014 | Q2 | — | 0,365 | — | — | — | — | 99 |
| 2013 | Q3 | — | 0,176 | — | — | — | — | 99 |
| 2012 | Q3 | — | 0,121 | — | — | — | — | 99 |
| 2011 | Q4 | — | 0,121 | — | — | — | — | 99 |
| 2010 | — | — | — | — | — | — | — | 99 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 18/141 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 56/356 |
| 2024 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 17/137 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 57/352 |
| 2023 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 26/132 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 69/354 |
| 2022 | INFECTIOUS DISEASES | SCIE | Q2 | Q2 | 35/96 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 65/278 |
| 2021 | INFECTIOUS DISEASES | SCIE | Q2 | Q2 | 39/95 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 68/279 |
| 2020 | INFECTIOUS DISEASES | SCIE | Q2 | Q2 | 26/93 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 76/276 |
| 2019 | INFECTIOUS DISEASES | SCIE | Q1 | Q2 | 23/92 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 64/271 |
| 2018 | INFECTIOUS DISEASES | SCIE | Q2 | Q3 | 40/89 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 109/267 |